A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

Eligibility Criteria

• * Ability to comprehend and willingness to sign a written ICF for the study.
• * Age 18 to 55 years, inclusive, at the time of signing the ICF.
• * Body mass index between 18.0 and 32.0 kg/m2 (inclusive).
• * Willingness to adhere to study-related prohibitions, restrictions, and procedures.
• * Ability to swallow and retain PO medication.
• * Willingness to avoid pregnancy or fathering children based on the criteria defined in the prootcol.
• * History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
• * History of rheumatologic/autoimmune disorders and immune deficiency/immunologic defects.
• * History of major bleeding or thrombosis, including myocardial infarction/stroke and pulmonary embolism/deep vein thrombosis.
• * Known tuberculosis infection that is active or participant-reported history of tuberculosis or treatment thereof.
• * Resting pulse \< 40 bpm or \> 100 bpm, confirmed by repeat testing at screening.
• * Presence of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).
• * Any major surgery within 12 weeks of screening.
• * Positive test for hepatitis B virus, hepatitis C virus, or HIV. Note: Participants whose results are compatible with prior immunization or immunity due to infection for hepatitis B may be included at the discretion of the investigator.
• * Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
• * Use of tobacco- or nicotine-containing products within 1 month of screening.
• * Women who are pregnant or breastfeeding.
• * eGFR \< 90 mL/min/1.73 m2 based on the CKD-EPI equation.
• * Any history of hypersensitivity or intolerance to itraconazole, rifampin, esomeprazole or any other PPI, or famotidine or any other H2 antagonist.